Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 341 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anti-Inflammatory Agents Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers

NCT00778193
View directory record Official record
Conditions
Gastroduodenal Ulcer
Interventions
Naproxen, Aspirin, Celecoxib, Clopidogrel, Placebo
Drug
Lead sponsor
Research Associates of New York, LLP
Other
Eligibility
18 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

NCT02841995
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Belumosudil (KD025)
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Duarte, California • Minneapolis, Minnesota • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 22, 2026, 10:02 AM EDT
Withdrawn Phase 4 Interventional

Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs

NCT00443963
View directory record Official record
Conditions
Dyspepsia
Interventions
Esomeprazole Magnesium
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

NCT02623426
View directory record Official record
Conditions
Uveitis, Macular Edema
Interventions
Dexamethasone intravitreal implant 0.7 mg, Intravitreal Methotrexate 400 µg, Intravitreal Ranibizumab 0.5 mg
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 4 Interventional Results available

ICE-T Pain Regimen for Total Laparoscopic Hysterectomy

NCT03987022
View directory record Official record
Conditions
Opioid Substitution Treatment
Interventions
Ketorolac, Opioids, Ice Packs, Tylenol, Motrin, Dilaudid Injectable Product, Percocet 5Mg-325Mg Tablet
Drug · Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions.

NCT03509675
View directory record Official record
Conditions
Oral Lichen Planus, Oral Lichenoid Mucositis, Oral Lichenoid Reaction
Interventions
Ibuprofen suspension 5mg/100ml, Placebos
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated No phase listed Observational

Anti-inflammatory Agents and Cholesterol Metabolism

NCT01279395
View directory record Official record
Conditions
Osteoarthritis
Interventions
Not listed
Lead sponsor
Winthrop University Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury

NCT00031551
View directory record Official record
Conditions
Stomatitis
Interventions
Etanercept, Placebo
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
16 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

NCT01854294
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GM604, Placebo comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 22, 2026, 10:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Anti-inflammatory Actions of Osteopathic Manipulative Treatment

NCT04177264
View directory record Official record
Conditions
Inflammation
Interventions
Occipito-Atlantal Decompression (OA DC), Sham Occipito-Atlantal Decompression (Sham OA DC), Splenic Lymphatic Pump Technique (SpLPT), Sham Splenic Lymphatic Pump Technique (Sham SpLPT), Transcutaneous Auricular Vagus Nerve Stimulation (taVNS), Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)
Procedure · Device
Lead sponsor
Burrell College of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Las Cruces, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting Phase 1 Interventional

GAIP ASD Research Study

NCT07622316
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, ASD, Autism Spectrum Disorder (ASD)
Interventions
Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione
Biological · Drug
Lead sponsor
Greater Atlanta Integrative Pediatrics
Other
Eligibility
3 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Roswell, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed No phase listed Observational

Exhaled Breath Condensate as a Measure of Airway Inflammation in Children With Asthma

NCT00078208
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 17 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Promoting Gastrointestinal Health and Reducing Subclinical Inflammation in Obese Individuals

NCT02602496
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Fruits and Vegetables, Whole Grain, Control
Other
Lead sponsor
University of Nebraska Lincoln
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting Phase 4 Interventional

Comprehensive Esophageal Diagnostics Study

NCT04641702
View directory record Official record
Conditions
Achalasia
Interventions
Atropine challenge, Esophageal muscle biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

NCT05531786
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Pacritinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 22, 2026, 10:02 AM EDT
Recruiting Not applicable Interventional

Anti-inflammatory Activities of Vitamin C Supplementation on the Gut Barrier Function in Adults With Obesity

NCT07151105
View directory record Official record
Conditions
Adequate Vitamin C Status, Inadequate Vitamin C Status
Interventions
Vitamin C Supplement + Low Vitamin C Diet, Placebo + Low Vitamin C Diet
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of CXA-10 in Healthy Volunteers

NCT02127190
View directory record Official record
Conditions
Acute Kidney Injury (Nontraumatic)
Interventions
CXA-10 emulsion, Placebo
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional

Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery

NCT00333918
View directory record Official record
Conditions
Pain, Inflammation
Interventions
bromfenac ophthalmic solution, placebo comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Phase 4 Interventional

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

NCT00346749
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol, Fluticasone Propionate/Salmeterol Combination Product
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 22, 2026, 10:02 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Anti-Inflammatory Effects of Exercise and Peanut Consumption

NCT03212144
View directory record Official record
Conditions
Peanut Consumption, High Intensity Aerobic Exercise
Interventions
High Intensity Interval Training, Peanut Consumption
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris

NCT01474798
View directory record Official record
Conditions
Acne Vulgaris
Interventions
RA-18C3
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 30 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Beverly Hills, California • St. Petersburg, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment

NCT00984815
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome, Chronic Soft Tissue Pain
Interventions
HZT-501
Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Chicago, Illinois • Morton Grove, Illinois • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 22, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL

NCT02998918
View directory record Official record
Conditions
Inflammation, Atherosclerosis, Cardiovascular Disease
Interventions
PolyResveratrol Supplementation, Curcumin Supplementation
Dietary Supplement
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 22, 2026, 10:02 AM EDT